Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Industry: Healthcare

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company is developing its lead drug candidate, CAPLYTA for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

Current Quote*
Last: $20.240
Change: -0.820
Book: $3.384
Volume: 319,919

As Of: 05/29 13:05 ET
*Quotes delayed by 20min.

Graphs for ITCI


3 Month Graph


6 Month Graph


1 Year Graph